BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 28828680)

  • 1. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents.
    Santillan C; Fowler K; Kono Y; Chernyak V
    Abdom Radiol (NY); 2018 Jan; 43(1):75-81. PubMed ID: 28828680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LI-RADS categories: concepts, definitions, and criteria.
    Santillan C; Chernyak V; Sirlin C
    Abdom Radiol (NY); 2018 Jan; 43(1):101-110. PubMed ID: 29038857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.
    Schellhaas B; Hammon M; Strobel D; Pfeifer L; Kielisch C; Goertz RS; Cavallaro A; Janka R; Neurath MF; Uder M; Seuss H
    Eur Radiol; 2018 Oct; 28(10):4254-4264. PubMed ID: 29675659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
    Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
    J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis.
    van der Pol CB; McInnes MDF; Salameh JP; Levis B; Chernyak V; Sirlin CB; Bashir MR; Allen BC; Burke LMB; Choi JY; Choi SH; Forner A; Fraum TJ; Giamperoli A; Jiang H; Joo I; Kang Z; Kierans AS; Kang HJ; Khatri G; Kim JH; Kim MJ; Kim SY; Kim YY; Kwon H; Lee JM; Lewis SC; McGinty KA; Mulazzani L; Park MS; Piscaglia F; Podgórska J; Reiner CS; Ronot M; Rosiak G; Song B; Song JS; Tang A; Terzi E; Wang J; Wang W; Wilson SR; Yokoo T
    Radiology; 2022 Feb; 302(2):326-335. PubMed ID: 34783596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI.
    Wilson SR; Lyshchik A; Piscaglia F; Cosgrove D; Jang HJ; Sirlin C; Dietrich CF; Kim TK; Willmann JK; Kono Y
    Abdom Radiol (NY); 2018 Jan; 43(1):127-142. PubMed ID: 28819825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
    Nakao S; Tanabe M; Okada M; Furukawa M; Iida E; Miyoshi K; Matsunaga N; Ito K
    Jpn J Radiol; 2019 Sep; 37(9):651-659. PubMed ID: 31321619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma.
    Fowler KJ; Potretzke TA; Hope TA; Costa EA; Wilson SR
    Abdom Radiol (NY); 2018 Jan; 43(1):149-157. PubMed ID: 28580538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features.
    Alhasan A; Cerny M; Olivié D; Billiard JS; Bergeron C; Brown K; Bodson-Clermont P; Castel H; Turcotte S; Perreault P; Tang A
    Abdom Radiol (NY); 2019 Feb; 44(2):517-528. PubMed ID: 30167771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.
    Horvat N; Nikolovski I; Long N; Gerst S; Zheng J; Pak LM; Simpson A; Zheng J; Capanu M; Jarnagin WR; Mannelli L; Do RKG
    Abdom Radiol (NY); 2018 Jan; 43(1):169-178. PubMed ID: 28765978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LI-RADS
    Chernyak V; Santillan CS; Papadatos D; Sirlin CB
    Abdom Radiol (NY); 2018 Jan; 43(1):111-126. PubMed ID: 28695233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas.
    Ehman EC; Behr SC; Umetsu SE; Fidelman N; Yeh BM; Ferrell LD; Hope TA
    Abdom Radiol (NY); 2016 May; 41(5):963-9. PubMed ID: 27193793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LI-RADS
    Chernyak V; Tang A; Flusberg M; Papadatos D; Bijan B; Kono Y; Santillan C
    Abdom Radiol (NY); 2018 Jan; 43(1):82-100. PubMed ID: 28647768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver Imaging Reporting and Data System: Discordance Between Computed Tomography and Gadoxetate-Enhanced Magnetic Resonance Imaging for Detection of Hepatocellular Carcinoma Major Features.
    Chernyak V; Flusberg M; Law A; Kobi M; Paroder V; Rozenblit AM
    J Comput Assist Tomogr; 2018; 42(1):155-161. PubMed ID: 28806321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
    Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
    Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
    Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
    Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
    [No Abstract]   [Full Text] [Related]  

  • 18. LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arterial Phase Hyperenhancement.
    Vernuccio F; Cannella R; Meyer M; Choudhoury KR; Gonzáles F; Schwartz FR; Gupta RT; Bashir MR; Furlan A; Marin D
    AJR Am J Roentgenol; 2019 Aug; 213(2):W57-W65. PubMed ID: 31039012
    [No Abstract]   [Full Text] [Related]  

  • 19. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
    De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018-based classification of liver lesions?
    Stocker D; Becker AS; Barth BK; Skawran S; Kaniewska M; Fischer MA; Donati O; Reiner CS
    Eur Radiol; 2020 May; 30(5):2922-2933. PubMed ID: 32020398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.